

# Paolo Gisondi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3246719/publications.pdf>

Version: 2024-02-01

260  
papers

11,436  
citations

31976

53  
h-index

37204

96  
g-index

265  
all docs

265  
docs citations

265  
times ranked

8763  
citing authors

#	ARTICLE	IF	CITATIONS
1	Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research, 2011, 303, 1-10.	1.9	690
2	European S3â€œGuidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1-70.	2.4	683
3	Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. British Journal of Dermatology, 2007, 157, 68-73.	1.5	543
4	Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. Journal of the American Academy of Dermatology, 2019, 80, 251-265.e19.	1.2	362
5	European S3â€œGuidelines on the systemic treatment of psoriasis vulgaris â€œ Update 2015 â€œ Short version â€œ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2277-2294.	2.4	353
6	The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis. Frontiers in Immunology, 2018, 9, 1549.	4.8	279
7	Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. Annals of the Rheumatic Diseases, 2008, 67, 26-30.	0.9	249
8	Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. Journal of Hepatology, 2009, 51, 758-764.	3.7	217
9	Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. American Journal of Clinical Nutrition, 2008, 88, 1242-7.	4.7	214
10	Psoriasis and the metabolic syndrome. Clinics in Dermatology, 2018, 36, 21-28.	1.6	211
11	Prevalence of symptoms experienced by patients with different clinical types of psoriasis. British Journal of Dermatology, 2004, 151, 594-599.	1.5	174
12	Antiâ€œtumour necrosis factorâ€œ therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 341-344.	2.4	166
13	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris â€œ Part 1: treatment and monitoring recommendations. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2461-2498.	2.4	149
14	Italian guidelines on the systemic treatments of moderateâ€œtoâ€œsevere plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 774-790.	2.4	140
15	Survival rate of antitumour necrosis factor-Î± treatments for psoriasis in routine dermatological practice: a multicentre observational study. British Journal of Dermatology, 2013, 169, 666-672.	1.5	138
16	Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Annals of the Rheumatic Diseases, 2012, 71, 553-556.	0.9	136
17	Factors associated with adverse COVID-19 outcomes in patients with psoriasisâ€œinsights from a global registryâ€œbased study. Journal of Allergy and Clinical Immunology, 2021, 147, 60-71.	2.9	136
18	Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. British Journal of Dermatology, 2008, 158, 1345-1349.	1.5	135

#	ARTICLE	IF	CITATIONS
19	Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2006, 155, 1165-1169.	1.5	120
20	Vitamin D status in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2012, 166, 505-510.	1.5	120
21	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 117-122.	1.2	120
22	The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis. <i>Rheumatology</i> , 2012, 51, 2058-2063.	1.9	116
23	European S3â€“Guideline on the systemic treatment of psoriasis vulgaris â€“ Update Apremilast and Secukinumab â€“ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1951-1963.	2.4	116
24	Chronic Plaque Psoriasis Is Associated with Increased Arterial Stiffness. <i>Dermatology</i> , 2009, 218, 110-113.	2.1	109
25	H1 histamine receptor mediates inflammatory responses in human keratinocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 1176-1182.	2.9	107
26	Impairment of Sexual Life in Patients with Psoriasis. <i>Dermatology</i> , 2007, 214, 144-150.	2.1	104
27	The impact of the <scp>COVID</scp> â€“19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. <i>British Journal of Dermatology</i> , 2020, 183, 373-374.	1.5	104
28	Interstitial granulomatous dermatitis: a distinct entity with characteristic histological and clinical pattern. <i>British Journal of Dermatology</i> , 2012, 166, 775-783.	1.5	99
29	Treatment Approaches to Moderate to Severe Psoriasis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2427.	4.1	96
30	Cutaneous manifestations of SARSâ€“CoVâ€“2 infection: a clinical update. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2499-2504.	2.4	96
31	Evidence for a â€“window of opportunityâ€™ in hidradenitis suppurativa treated with adalimumab: a retrospective, realâ€“life multicentre cohort study*. <i>British Journal of Dermatology</i> , 2021, 184, 133-140.	1.5	88
32	Psoriasis and Atherothrombotic Diseases: Disease-Specific and Nonâ€“Disease-Specific Risk Factors. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 313-324.	2.7	86
33	Preliminary Evidence That Subclinical Enthesopathy May Predict Psoriatic Arthritis in Patients with Psoriasis. <i>Journal of Rheumatology</i> , 2011, 38, 2691-2692.	2.0	86
34	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	5.9	86
35	Dermatologists and SARSâ€“CoVâ€“2: the impact of the pandemic on daily practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1196-1201.	2.4	85
36	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris â€“ Part 2: specific clinical and comorbid situations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 281-317.	2.4	84

#	ARTICLE	IF	CITATIONS
37	Biologic therapies in psoriasis: A new therapeutic approach. <i>Autoimmunity Reviews</i> , 2007, 6, 515-519.	5.8	83
38	Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities. <i>Frontiers in Pharmacology</i> , 2020, 11, 117.	3.5	80
39	Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e30-41.	2.4	75
40	The link between enthesitis and arthritis in psoriatic arthritis: a switch to a vascular phenotype at insertions may play a role in arthritis development. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 992-995.	0.9	73
41	Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 217.	4.1	73
42	Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. <i>European Journal of Dermatology</i> , 2005, 15, 279-83.	0.6	73
43	Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 126-131.	1.2	71
44	Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities. <i>Frontiers in Medicine</i> , 2015, 2, 1.	2.6	68
45	Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. <i>British Journal of Dermatology</i> , 2013, 168, 1124-1127.	1.5	67
46	Pruritus as a Distinctive Feature of Type 2 Inflammation. <i>Vaccines</i> , 2021, 9, 303.	4.4	66
47	Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. <i>British Journal of Dermatology</i> , 2013, 168, 749-755.	1.5	65
48	Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 567-579.	6.7	65
49	The clinical spectrum of COVID-19-associated cutaneous manifestations: An Italian multicenter study of 200 adult patients. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1356-1363.	1.2	61
50	Folic acid in general medicine and dermatology. <i>Journal of Dermatological Treatment</i> , 2007, 18, 138-146.	2.2	59
51	Targeting tumor necrosis factor $\hat{\pm}$ in psoriasis and psoriatic arthritis. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1085-1096.	3.4	58
52	Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines. <i>Journal of Clinical Medicine</i> , 2021, 10, 5344.	2.4	58
53	Psoriasis and systemic inflammation: underdiagnosed enthesopathy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 3-8.	2.4	57
54	The role of the interleukin $\hat{\pm}$ 23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1695-1706.	2.4	57

#	ARTICLE	IF	CITATIONS
55	Immunogenicity of anti-TNF± therapy in psoriasis: a clinical issue?. Expert Opinion on Biological Therapy, 2013, 13, 1673-1682.	3.1	56
56	Immunoregulation of Allergic Contact Dermatitis. Journal of Dermatology, 2004, 31, 264-270.	1.2	55
57	Usefulness of the Framingham Risk Score in Patients With Chronic Psoriasis. American Journal of Cardiology, 2010, 106, 1754-1757.	1.6	53
58	Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Annals of the Rheumatic Diseases, 2022, 81, 68-73.	0.9	53
59	Phenotypes of atopic dermatitis. JDDG - Journal of the German Society of Dermatology, 2011, 9, 12-20.	0.8	52
60	Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. Annals of the Rheumatic Diseases, 2017, 76, 1591-1597.	0.9	52
61	Prevalence of most common skin diseases in Europe: a population-based study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1088-1096.	2.4	52
62	Ultrasonography reveals nail thickening in patients with chronic plaque psoriasis. Archives of Dermatological Research, 2012, 304, 727-732.	1.9	51
63	Mild Cognitive Impairment in Patients with Moderate to Severe Chronic Plaque Psoriasis. Dermatology, 2014, 228, 78-85.	2.1	51
64	Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 282-287.	2.4	50
65	Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment. Journal of the American Academy of Dermatology, 2020, 83, 285-287.	1.2	49
66	Pimecrolimus in dermatology: atopic dermatitis and beyond. International Journal of Clinical Practice, 2005, 59, 969-974.	1.7	47
67	Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab. Immunologic Research, 2013, 56, 382-389.	2.9	46
68	Hyperuricemia in patients with chronic plaque psoriasis. Journal of the American Academy of Dermatology, 2014, 70, 127-130.	1.2	45
69	Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience. Journal of Allergy and Clinical Immunology, 2021, 147, 558-560.e1.	2.9	44
70	Targeting Tumor Necrosis Factor-α in the Therapy of Psoriasis. Inflammation and Allergy: Drug Targets, 2004, 3, 175-183.	3.1	43
71	Advanced Glycation End Products in the Pathogenesis of Psoriasis. International Journal of Molecular Sciences, 2017, 18, 2471.	4.1	43
72	Insufficient Knowledge Among Psoriasis Patients Can Represent a Barrier to Participation in Decision-making. Acta Dermato-Venereologica, 2006, 86, 528-534.	1.3	40

#	ARTICLE	IF	CITATIONS
73	Considerations for Systemic Treatment of Psoriasis in Obese Patients. American Journal of Clinical Dermatology, 2016, 17, 609-615.	6.7	40
74	Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert Opinion on Biological Therapy, 2021, 21, 271-277.	3.1	40
75	Microcirculatory modifications of psoriatic lesions during topical therapy. Skin Research and Technology, 2009, 15, 135-138.	1.6	39
76	Perception of Disease and Doctor-Patient Relationship Experienced by Patients with Psoriasis. American Journal of Clinical Dermatology, 2009, 10, 325-330.	6.7	39
77	Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. British Journal of Dermatology, 2015, 172, 1613-1620.	1.5	36
78	A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). British Journal of Dermatology, 2017, 177, 197-205.	1.5	36
79	Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. Journal of the American Academy of Dermatology, 2021, 85, 572-581.	1.2	36
80	Psoriasis, the liver, and the gastrointestinal tract. Dermatologic Therapy, 2010, 23, 155-159.	1.7	35
81	Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: A multicentric retrospective analysis. Journal of Dermatological Treatment, 2016, 27, 395-398.	2.2	35
82	Association Between Short-term Exposure to Environmental Air Pollution and Psoriasis Flare. JAMA Dermatology, 2022, 158, 375.	4.1	35
83	Effectiveness and Safety of Acitretin in Children with Plaque Psoriasis: A Multicenter Retrospective Analysis. Pediatric Dermatology, 2016, 33, 530-535.	0.9	34
84	State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. Current Opinion in Pharmacology, 2019, 46, 90-99.	3.5	34
85	Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers. Journal of Dermatology, 2020, 47, 578-582.	1.2	34
86	Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. Dermatology and Therapy, 2021, 11, 235-252.	3.0	34
87	Adult atopic dermatitis: a review. Giornale Italiano Di Dermatologia E Venereologia, 2016, 151, 403-11.	0.8	34
88	Balneotherapy for atopic dermatitis in children at Comano spa in Trentino, Italy. Journal of Dermatological Treatment, 2011, 22, 366-371.	2.2	32
89	Heat urticaria: a revision of published cases with an update on classification and management. British Journal of Dermatology, 2016, 175, 473-478.	1.5	32
90	Metabolic comorbidities and psoriasis. Acta Dermatovenerologica Croatica, 2010, 18, 297-304.	0.1	32

#	ARTICLE	IF	CITATIONS
91	Severe Impairment of Quality of Life in Hailey-Hailey Disease. <i>Acta Dermato-Venereologica</i> , 2005, 85, 132-135.	1.3	31
92	C-Reactive Protein and Markers for Thrombophilia in Patients with Chronic Plaque Psoriasis. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 1195-1202.	2.1	31
93	Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 863-869.	2.4	31
94	Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e770-e772.	2.4	31
95	Autoimmune progesterone dermatitis. <i>Gynecological Endocrinology</i> , 2006, 22, 54-56.	1.7	30
96	Efficacy of a Single Educative Intervention in Patients with Chronic Plaque Psoriasis. <i>Dermatology</i> , 2009, 219, 316-321.	2.1	30
97	Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy. <i>Dermatology and Therapy</i> , 2014, 4, 1-9.	3.0	30
98	Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. <i>Journal of Dermatological Treatment</i> , 2018, 29, 217-219.	2.2	30
99	Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. <i>British Journal of Dermatology</i> , 2019, 180, 1547-1548.	1.5	30
100	Balneotherapy for chronic plaque psoriasis at Comano spa in Trentino, Italy. <i>Dermatologic Therapy</i> , 2008, 21, S31-S38.	1.7	29
101	Weight Reduction Alone May Not Be Sufficient to Maintain Disease Remission in Obese Patients with Psoriasis: A Randomized, Investigator-Blinded Study. <i>Dermatology</i> , 2012, 224, 31-37.	2.1	29
102	Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies. <i>Vaccines</i> , 2020, 8, 769.	4.4	29
103	Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. <i>Journal of Dermatological Treatment</i> , 2013, 24, 305-311.	2.2	28
104	A systematic review of treatments for pityriasis lichenoides. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2039-2049.	2.4	28
105	Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1853-1859.	2.4	27
106	Psoriasis is not associated with cognition, brain imaging markers, and risk for dementia: The Rotterdam Study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 671-680.	1.2	27
107	Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 749-751.	6.7	27
108	The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments. <i>Vaccines</i> , 2020, 8, 728.	4.4	27

#	ARTICLE	IF	CITATIONS
109	Cardiometabolic Comorbidities and the Approach to Patients with Psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 14-21.	0.4	26
110	Incidence of respiratory and allergic symptoms in Italian and immigrant children. <i>Respiratory Medicine</i> , 2011, 105, 204-210.	2.9	26
111	Psodisk, a new visual method for assessing the burden of psoriasis on patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1163-1166.	2.4	26
112	Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1763.	4.3	26
113	Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 693-700.	2.4	26
114	Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey*. <i>British Journal of Dermatology</i> , 2021, 185, 80-90.	1.5	26
115	Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1277-1288.	3.3	26
116	Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy. <i>British Journal of Dermatology</i> , 2014, 171, 884-890.	1.5	25
117	Annular Lichenoid Dermatitis of Youth: Report of Six New Cases with Review of the Literature. <i>Dermatology</i> , 2015, 231, 195-200.	2.1	25
118	Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, 1-78.	0.2	25
119	The pharmacological management of patients with comorbid psoriasis and obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 863-872.	1.8	23
120	Ultrasonography of the nail unit reveals quantitative and qualitative alterations in patients with psoriasis and psoriatic arthritis. <i>Medical Ultrasonography</i> , 2018, 20, 177.	0.8	23
121	Comparison of patients' and providers' severity evaluation of oral mucosal conditions. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 69-76.	1.2	22
122	Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 247-253.	3.2	22
123	Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis. <i>Journal of Dermatological Science</i> , 2015, 78, 149-151.	1.9	21
124	Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study. <i>Acta Dermato-Venereologica</i> , 2016, 96, 251-252.	1.3	21
125	Adalimumab in severe plaque psoriasis of childhood: A multicenter, retrospective real-life study up to 52-weeks observation. <i>Dermatologic Therapy</i> , 2019, 32, e13091.	1.7	21
126	Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1156-1163.	2.4	20



#	ARTICLE	IF	CITATIONS
127	Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review. <i>Rheumatology and Therapy</i> , 2020, 7, 271-285.	2.3	20
128	Impact of the COVID-19 pandemic on melanoma diagnosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e714-e715.	2.4	20
129	Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 133-136.	0.8	20
130	Management of Patients with Psoriasis Treated with Biological Drugs Needing a Surgical Treatment. <i>Drug Development Research</i> , 2014, 75, S24-S26.	2.9	19
131	Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. <i>British Journal of Dermatology</i> , 2017, 177, e325-e326.	1.5	19
132	Optimization of systemic treatments for chronic plaque psoriasis. Recommendations for switching and transitioning. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2013, 148, 1-10.	0.8	19
133	The Diagnostic and Therapeutic Challenge of Early Psoriatic Arthritis. <i>Dermatology</i> , 2010, 221, 6-14.	2.1	18
134	Imaging in Psoriasis and Psoriatic Arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010, 37, 448-452.	2.0	18
135	Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e636-e640.	2.4	18
136	TNF- $\alpha$ inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 591-598.	3.0	18
137	Etanercept biosimilar SB 4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. <i>British Journal of Dermatology</i> , 2019, 180, 409-410.	1.5	17
138	Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2020, 183, 397-398.	1.5	17
139	Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review. <i>Dermatology and Therapy</i> , 2021, 11, 695-705.	3.0	17
140	Preference for Telemedicine Versus In-Person Visit Among Patients with Psoriasis Receiving Biological Drugs. <i>Dermatology and Therapy</i> , 2021, 11, 1333-1343.	3.0	17
141	Public perception of dermatology and dermatologists in Italy: results from a population-based national survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2119-2123.	2.4	16
142	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , 2018, 35, 545-562.	2.9	16
143	An itchy vesiculobullous eruption in a patient with chronic lymphocytic leukaemia. <i>International Journal of Clinical Practice</i> , 2004, 58, 1177-1179.	1.7	15
144	Concept of Remission in Chronic Plaque Psoriasis. <i>Journal of rheumatology Supplement, The</i> , 2015, 93, 57-60.	2.2	15

#	ARTICLE	IF	CITATIONS
145	Consensus on the management of patients with psoriatic arthritis in a dermatology setting. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 515-528.	2.4	15
146	Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients. Dermatologic Therapy, 2020, 33, e13979.	1.7	15
147	Erythema nodosum: etiological factors and relapses in a retrospective cohort study. European Journal of Dermatology, 2010, 20, 773-7.	0.6	15
148	Primary Cutaneous CD4 <sup>+</sup> Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series. Journal of Cutaneous Medicine and Surgery, 2017, 21, 502-506.	1.2	14
149	Serum IFI16 and anti-IFI16 antibodies in psoriatic arthritis. Clinical and Experimental Immunology, 2019, 199, 88-96.	2.6	14
150	IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review. Dermatologic Therapy, 2021, 34, e14889.	1.7	14
151	Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks. Journal of Clinical Medicine, 2020, 9, 3594.	2.4	13
152	Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: A case study. Journal of Dermatological Treatment, 2006, 17, 172-175.	2.2	12
153	Treatment Adherence to Different Etanercept Regimens, Continuous vs. Intermittent, in Patients Affected by Plaque-Type Psoriasis. Drug Development Research, 2014, 75, S31-S34.	2.9	12
154	Impact of training on concordance among rheumatologists and dermatologists in the assessment of patients with psoriasis and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2016, 46, 305-311.	3.4	12
155	Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome. Dermatologic Therapy, 2020, 33, e14281.	1.7	12
156	Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study. Acta Dermato-Venereologica, 2021, 101, adv00422.	1.3	12
157	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology, 2022, 158, 561.	4.1	12
158	Patients with Psoriasis Have a Higher Prevalence of Parental Cardiovascular Disease. Dermatology, 2011, 222, 330-335.	2.1	11
159	Psoriasin (S100A7) is increased in the serum of patients with moderate-to-severe psoriasis. British Journal of Dermatology, 2020, 182, 1502-1503.	1.5	11
160	Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. British Journal of Dermatology, 2022, 187, 254-256.	1.5	11
161	Update on the Management of Pediatric Psoriasis: An Italian Consensus. Dermatology and Therapy, 2022, 12, 1753-1775.	3.0	11
162	Hyperuricemia in Patients with Chronic Plaque Psoriasis. Drug Development Research, 2014, 75, S70-2.	2.9	10

#	ARTICLE	IF	CITATIONS
163	Skin rash and arthritis a simplified appraisal of less common associations. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 679-688.	2.4	10
164	Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. Dermatologic Therapy, 2017, 30, e12503.	1.7	10
165	The psoriatic patient profile for infliximab. European Review for Medical and Pharmacological Sciences, 2011, 15, 1445-51.	0.7	10
166	Monkeypox virus infection: what dermatologist needs to know?. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	10
167	A randomized controlled trial to evaluate short-term treatment with eosin vs. topical steroids in psoriasis. Clinical and Experimental Dermatology, 2009, 34, 304-308.	1.3	9
168	Effects of secukinumab on serum adipocytokines: preliminary data. Reumatismo, 2017, 69, 105.	0.9	9
169	Initial assessment of the early arthritis for psoriatic patients diagnostic questionnaire in dermatology clinics in Australia, Korea and China. International Journal of Rheumatic Diseases, 2019, 22, 1512-1520.	1.9	9
170	Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis. Dermatology, 2020, 236, 329-335.	2.1	9
171	Increased red blood cell distribution width in patients with plaque psoriasis. Journal of Medical Biochemistry, 2021, 40, 199-201.	1.7	9
172	Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer. Dermatology, 2021, 237, 1-5.	2.1	9
173	Insights into Sarsâ€CoVâ€2 vaccination in patients with chronic plaque psoriasis on systemic treatments. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e361-e362.	2.4	9
174	Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence. Journal of Investigative Dermatology, 2021, , .	0.7	9
175	Hidradenitis suppurativa and adalimumab in the COVID-19 era. European Journal of Dermatology, 2020, 30, 748-749.	0.6	9
176	Impact of TNF-Î± antagonists on the quality of life in selected skin diseases. Giornale Italiano Di Dermatologia E Venereologia, 2013, 148, 243-8.	0.8	9
177	Psoriasis and Metabolic Comorbidities: The Importance of Well-Designed Prospective Studies. Dermatology, 2008, 217, 222-224.	2.1	8
178	<scp>PSOCUBE</scp>, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidenceâ€based algorithm. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1310-1317.	2.4	8
179	Glomerular filtration rate in patients with psoriasis treated with etanercept. Journal of International Medical Research, 2016, 44, 106-108.	1.0	8
180	Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remission. British Journal of Dermatology, 2019, 181, 1319-1320.	1.5	8

#	ARTICLE	IF	CITATIONS
181	Clinical features and treatments of transient acantholytic dermatosis (Grover's disease): a systematic review. JDDG - Journal of the German Society of Dermatology, 2020, 18, 826-833.	0.8	8
182	Brodalumab in the treatment of chronic plaque psoriasis. Expert Opinion on Biological Therapy, 2020, 20, 1175-1186.	3.1	8
183	Risk of lymphohematologic malignancies in patients with chronic plaque psoriasis: A systematic review with meta-analysis. Journal of the American Academy of Dermatology, 2021, , .	1.2	8
184	Biological agents targeting interleukin-13 for atopic dermatitis. Expert Opinion on Biological Therapy, 2022, 22, 651-659.	3.1	8
185	Dupilumab for recalcitrant Kimura disease. Dermatologic Therapy, 2022, 35, .	1.7	8
186	Psoriasis and Risk of Myocardial Infarction. JAMA - Journal of the American Medical Association, 2007, 297, 361.	7.4	7
187	Patients' perspectives in the management of psoriasis: the Italian results of the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Journal of Dermatological Treatment, 2017, 28, 390-393.	2.2	7
188	Kyrle's disease effectively treated with oral isotretinoin. Journal of Dermatological Treatment, 2018, 29, 630-632.	2.2	7
189	Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis. BioDrugs, 2021, 35, 469-471.	4.6	7
190	Treatment patterns with systemic antipsoriatic agents in childhood psoriasis: an Italian database analysis. Italian Journal of Dermatology and Venereology, 2017, 152, 327-332.	0.2	7
191	How to improve adherence to treatment in patients with mild-to-moderate psoriasis. Giornale Italiano Di Dermatologia E Venereologia, 2018, 153, 692-697.	0.8	7
192	Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis. Dermatology and Therapy, 2022, 12, 1303-1311.	3.0	7
193	Treatment of Psoriasis with Efalizumab in Patients with Hepatitis C Viral Infection: Report of Five Cases. Dermatology, 2009, 219, 158-161.	2.1	6
194	Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2839-2845.	2.4	6
195	Consensus on the place in therapy of TNF inhibitors in the treatment of patients with chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e470-e472.	2.4	6
196	A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis. Expert Review of Clinical Pharmacology, 2020, 13, 481-491.	3.1	6
197	Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 797-806.	2.4	6
198	Attitude to treatment of patients with psoriasis attending spa center. Giornale Italiano Di Dermatologia E Venereologia, 2012, 147, 483-9.	0.8	6

#	ARTICLE	IF	CITATIONS
199	Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1579-1584.	3.1	6
200	Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region. <i>Journal of Dermatological Treatment</i> , 2017, 28, 129-135.	2.2	5
201	High prevalence of alcohol use disorders in patients with inflammatory skin diseases applies to both psoriasis and eczema. <i>British Journal of Dermatology</i> , 2017, 177, 606-607.	1.5	5
202	Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00576.	1.3	5
203	Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04153.	0.5	5
204	Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end-products. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 80-85.	1.3	5
205	Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease. <i>Vaccines</i> , 2022, 10, 646.	4.4	5
206	Combination of efalizumab and acitretin in chronic plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 22, 070619172136002-???	2.4	4
207	Validation and Field Performance of the Italian Version of the Psoriatic Arthritis Screening and Evaluation (PASE) Questionnaire. <i>Acta Dermato-Venereologica</i> , 2014, 96, 96-101.	1.3	4
208	The multidimensional burden of psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 13-14.	1.5	4
209	A multicenter retrospective case-control study on Suspension of TNF-inhibitors and Outcomes in Psoriatic patients (STOP study). <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 392-399.	0.8	4
210	Glomerular filtration rate in patients with moderate-to-severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e244-e246.	2.4	4
211	Does systemic treatment of psoriasis reduce the risk of comorbidities?. <i>British Journal of Dermatology</i> , 2020, 182, 823-824.	1.5	4
212	Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study. <i>Dermatologic Therapy</i> , 2021, 34, e14949.	1.7	4
213	Undertreatment in adult patients with moderate-to-severe atopic dermatitis and other chronic inflammatory skin diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2168-2169.	2.4	4
214	Psychological Stress and Salivary Cortisol Levels in Patients with Plaque Psoriasis. <i>Journal of Personalized Medicine</i> , 2021, 11, 1069.	2.5	4
215	Early predictors of psoriatic arthritis: a delphi based consensus from Italian dermatology centers. <i>Italian Journal of Dermatology and Venereology</i> , 2022, , .	0.2	4
216	Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2019, 182, 175-179.	1.5	3

#	ARTICLE	IF	CITATIONS
217	Relapse of psoriatic arthritis in patients with active psoriasis switched from tumour necrosis factor- $\alpha$ to interleukin-17A inhibitor. <i>British Journal of Dermatology</i> , 2019, 181, 624-626.	1.5	3
218	Low dose acitretin versus methotrexate in the treatment of palmoplantar psoriasis: a case series. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e246-e247.	2.4	3
219	Place of apremilast in the real-life treatment of patients with plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 13-13.	2.4	3
220	Disseminated lupus vulgaris. <i>European Journal of Dermatology</i> , 2003, 13, 500-2.	0.6	3
221	Investigating psoriasis awareness among patients in Italy: validation of a questionnaire. <i>European Review for Medical and Pharmacological Sciences</i> , 2014, 18, 3435-52.	0.7	3
222	Is risankizumab as needed administration a good option for patients with plaque psoriasis?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	3
223	The multifaceted association between psoriasis and obesity. <i>British Journal of Dermatology</i> , 2019, 180, 24-24.	1.5	2
224	Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e355-e357.	2.4	2
225	Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e709-e711.	2.4	2
226	Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 455-459.	0.2	2
227	The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1099-1107.	0.8	2
228	AB0821...Baseline Characteristics of Patients with Moderate to Severe Psoriatic Arthritis: Post-Hoc Analysis of Responders vs Non-Responders to Etanercept. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1174-1174.	0.9	1
229	Dermatoepidemiology; what's up people?. <i>British Journal of Dermatology</i> , 2015, 173, 881-883.	1.5	1
230	Recognizing the differential impact of site of involvement on quality of life in dermatology. <i>British Journal of Dermatology</i> , 2019, 181, 229-230.	1.5	1
231	Visual Vignette. <i>Endocrine Practice</i> , 2020, 26, 253.	2.1	1
232	Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination. <i>Vaccine</i> , 2020, 38, 3808-3809.	3.8	1
233	Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature. <i>Case Reports in Dermatology</i> , 2021, 13, 282-288.	0.8	1
234	Hypochondriasis and Personality Traits of Patients with Chronic Plaque Psoriasis. <i>Dermatology</i> , 2022, 238, 276-282.	2.1	1

#	ARTICLE	IF	CITATIONS
235	Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy. <i>Global &amp; Regional Health Technology Assessment</i> , 0, 8, 120-130.	0.1	1
236	Metabolic Syndrome in Psoriasis. , 2010, , 95-98.		1
237	Predictors of subsequent primary melanoma: a caseâ€“control study. <i>Archives of Dermatological Research</i> , 2022, 314, 881-885.	1.9	1
238	Clinical profile and co-infections of urethritis in males. <i>Italian Journal of Dermatology and Venereology</i> , 2021, , .	0.2	1
239	Skin adverse reactions to Sarsâ€“CoVâ€“2 vaccination: a relevant responsibility issue for dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 165-166.	2.4	1
240	Non-Alcoholic Fatty Liver Disease Is Associated With Reduced Glomerular Filtration Rate in Patients With Chronic Plaque Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, , 120347542110669.	1.2	1
241	Scurvy as Presenting Sign of Anorexia Nervosa. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 645-645.	1.2	1
242	Seminars in Research 2013. <i>Drug Development Research</i> , 2014, 75, S1-S2.	2.9	0
243	Therapeutic insights from the British Association of Dermatologists Biologic Interventions Register. <i>British Journal of Dermatology</i> , 2015, 173, 329-330.	1.5	0
244	Skin moisturization for xerosis related to targeted anticancer therapies. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e33.	1.2	0
245	Could maternal stress increase the risk of developing psoriasis in the offspring?. <i>British Journal of Dermatology</i> , 2017, 176, 569-570.	1.5	0
246	Severe cutaneous aluminum reaction to quadrivalent human papillomavirus vaccine treated with cyclosporin. <i>Journal of Dermatology</i> , 2017, 44, e332-e333.	1.2	0
247	Image Gallery: Pyoderma gangrenosum of the penis. <i>British Journal of Dermatology</i> , 2018, 178, e62.	1.5	0
248	Is the routine screening for hyperhomocysteinaemia recommended in patients with chronic plaque psoriasis?. <i>British Journal of Dermatology</i> , 2019, 180, 262-263.	1.5	0
249	Considerations in association studies in dermatoepidemiology. <i>British Journal of Dermatology</i> , 2021, 185, 1-2.	1.5	0
250	The Handbook of Differential Diagnosis for the Dermatologist. <i>European Journal of Dermatology</i> , 2009, 19, 195-195.	0.6	0
251	SAT0412â€“...ACCURACY OF AN INSTRUMENT FOR SCREENING PSORIATIC ARTHRITIS AMONG PSORIATIC PATIENTS: RESULTS FROM THE MULTICENTRE ITALIAN STUDY HERACLES (SCREENING STRATEGIES FOR) Tj ETQq1 1 0.784314 rgBT /Overlock 10 of the Rheumatic Diseases. 2020, 79, 1158.2-1159.	0.9	0
252	Ki67/MART1 and p63/SOX10 dual immunohistochemistry allows a correct interpretation of the melanocytic component in the diagnosis of pigmented pilomatricoma. <i>Indian Journal of Dermatology</i> , 2021, 66, 525.	0.3	0

#	ARTICLE	IF	CITATIONS
253	Corymbose Syphilis. Sexually Transmitted Diseases, 2022, 49, e85-e86.	1.7	0
254	The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases. Italian Journal of Dermatology and Venereology, 2022, , .	0.2	0
255	Dermoscopic features of nevoid melanoma: a retrospective study with systematic literature review. Italian Journal of Dermatology and Venereology, 2022, , .	0.2	0
256	Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	0
257	Variations of symptoms of atopic dermatitis and psoriasis in relation to menstrual cycle. Journal of the American Academy of Dermatology, 2021, , .	1.2	0
258	In vitro cell culture of amniotic fluid keratinocytes on amniotic membrane: the ideal tissue for repairing skin ulcers. European Review for Medical and Pharmacological Sciences, 2021, 25, 49-55.	0.7	0
259	Paradoxical Effect on Epidermal Barrier of Anti-TNF-alpha Treatment for Psoriasis.. Journal of Clinical and Aesthetic Dermatology, 2022, 15, 36-38.	0.1	0
260	Association between short-term exposure to environmental air pollution and psoriasis flare. Bone Reports, 2022, 16, 101441.	0.4	0